TGFBI and type 2 diabetes mellitus: Interestingly, plasma EV-associated TGFBI was significantly elevated in obese patients with a history of T2D compared to non-diabetic patients, and mimecan-EVs were higher in obese plasma compared to those in healthy lean individuals and may therefore represent candidate biomarkers to monitor T2D status in obese patients or to track obesity, respectively.